Effect of Antibiotics on Gut Microbiome and Plasma Metabolome

Summary

In recent years it has been observed that the gut microbiome can produce metabolites into systemic circulation and thus have important health effects even outside the gastrointestinal system. These metabolites may play a role in the pathogenesis of common public health problems such as diabetes, obesity and cardiovascular disorders. Modern techniques of mass spectrometry-based metabolomics from peripheral blood and gut metagenome sequencing now enable detailed examination of these processes. Using samples from the FINRISK 2002 cohort, collected by the National Institute for Health and Welfare, we are currently determining the gut microbiome and plasma metabolome from \> 7000 participants with 15 years of follow-up for various health outcomes. This is one of the largest materials of its kind world-wide. The design does not, however, allow us to draw causal conclusions on the roles of gut bacteria in the composition of plasma metabolome. To enable conclusions which go beyond statistical associations, we now propose an extension to the FINRISK 2002 study, where we alter the gut bacteriome with a short course of antibiotics and then examine whether a change in plasma metabolomics profile will follow. At the same time the trial will give important novel information about the effects of commonly used antibiotics on gut bacteriome and on general health.

Conditions

• Microbial Colonization

Interventions

DRUG

Amoxicillin

Amoxicillin (po) 500 mg x 3 per day for 3 days.

DRUG

Azithromycin

Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.

DRUG

Vancomycin

Vancomycin (po) 125 mg x 4 per day for 3 days.

Sponsors & Collaborators

• University of California, San Diego

  collaborator OTHER

• Brigham and Women's Hospital

  collaborator OTHER

• Finnish Institute for Health and Welfare

  lead OTHER_GOV

Principal Investigators

• Aki Havulinna, MD, PhD · Finnish Institute for Health and Welfare

• Markus Perola, DSc (tech.) · Finnish Institute for Health and Welfare

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

40 Years

Max Age

74 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2017-10-15

Primary Completion

2017-12-15

Completion

2017-12-15

Countries

• Finland

Study Locations